Combination therapy for metastatic colorectal cancer with a KRAS G12C mutation is well tolerated and exhibits antitumor effects.

Published Date: 10 Apr 2024

Pooled results showed promising anti-tumor effects when the anti-EGFR antibody cetuximab and the KRAS G12C inhibitor adagrasib were combined in patients with metastatic colorectal cancer (CRC) that had a KRAS G12C mutation.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot